Introduction
A medical device that fails does so in contact with a patient. A catheter material can release a harmful substance, a pump can deliver the wrong dose, and a confusing interface can lead a clinician to misuse a device. Medical device safety assessment is how manufacturers find these hazards early, judge whether the resulting risks are acceptable, and prove that their controls work.
The work follows recognized frameworks. ISO 14971 governs risk management across the device lifecycle, while ISO 10993 guides biological evaluation of patient-contacting materials. EU MDR and FDA expectations differ in structure, but both require structured safety evidence. This guide explains how the pieces fit together, what documentation regulators expect, and when specialist support helps.
Quick Summary
Medical device safety assessment is the structured process of identifying hazards, estimating and evaluating risks, applying controls, and documenting that residual risk is acceptable for the device's intended use. ISO 14971 provides the risk management framework. ISO 10993 supports biological evaluation, with chemical characterization and toxicological risk assessment addressing material-related hazards. Testing is selected based on device risk, not applied universally. The resulting evidence supports EU MDR technical documentation and FDA submissions, but it does not by itself guarantee clearance, approval, or CE marking.
What Is Medical Device Safety Assessment?
Medical device safety assessment is a lifecycle risk-based evaluation that identifies hazards, estimates and evaluates risks, implements and verifies controls, and documents acceptable residual risk for a device's intended use. It is broader than any single laboratory test.
In practice it combines several activities: hazard identification, risk analysis, risk evaluation against defined acceptability criteria, risk control, verification that controls are effective, evaluation of residual risk, and traceable safety documentation. Testing generates evidence within this process, but a passing test report alone does not demonstrate that the device is safe.
Quick Answer: How Is Medical Device Safety Assessment Conducted?
Manufacturers define the device and its intended use, identify hazards, and estimate and evaluate risks. They implement risk controls, determine which testing and evaluation is relevant, and assess biological and toxicological safety where applicable. Controls are then verified, residual and overall benefit-risk are evaluated, and safety documentation is prepared. The risk management information is maintained and updated throughout the device lifecycle using production and post-market data.
Why Is Medical Device Safety Assessment Important?
It protects patients and users, supports device performance, and gives manufacturers a defensible basis for design decisions. It also feeds quality management and post-market monitoring, so safety is managed as an ongoing activity rather than a pre-launch milestone.
Patient Safety and Risk Reduction
Risk management forces a manufacturer to ask what could go wrong, how likely it is, and how severe the harm would be. Hazards range from toxic leachables and sharp edges to software errors and ambiguous labeling. Identifying and controlling them in design is far more effective than relying on warnings or post-market correction.
Regulatory and Product Development Benefits
Structured safety evidence shortens review questions because reviewers can trace each hazard to its control and its verification. During development it also guides material choices, supplier selection, and test planning, which reduces late redesigns. Gaps found at design freeze are cheaper to fix than gaps raised in a deficiency letter.
What Are the Main Components of Medical Device Safety Assessment?
Hazard Identification
Manufacturers systematically list hazards across categories that apply to the device: biological (for example sensitizing materials), chemical (leachables, sterilant residues), mechanical (fracture, sharp edges), electrical, thermal, software-related, and usability-related hazards. A hazard is a potential source of harm; the hazardous situation, and the sequence of events leading to it, are analyzed next.
Risk Analysis and Evaluation
Risk is estimated from the severity of harm and the probability that it occurs. Each estimated risk is compared with risk acceptability criteria defined in the risk management plan. Criteria must be set in advance and justified, since moving thresholds after the fact weakens the whole file.
Risk Control
ISO 14971 sets a hierarchy. Manufacturers should prefer inherently safe design, then protective measures in the device or manufacturing process, and use information for safety such as labeling and training only where higher-priority options are not sufficient. Warnings alone rarely control a design problem.
Residual Risk Evaluation
Controls can reduce a risk without eliminating it, and they can introduce new hazards. After controls are implemented and verified, remaining risk is re-evaluated individually and then as an overall residual risk for the device.
Benefit-Risk Analysis
When residual risk is not acceptable by the established criteria, or when overall residual risk must be judged, benefit-risk analysis weighs clinical benefit against remaining risk. It must be scientifically justified, using clinical and performance evidence rather than assertion.
ISO 14971 Risk Management for Medical Devices
ISO 14971 is the international standard for applying risk management to medical devices. The current edition is ISO 14971:2019. It describes risk management planning, hazard identification, risk analysis and evaluation, risk control, evaluation of overall residual risk, risk management review, and collection of production and post-production information. It is a process standard: it does not set safety limits or guarantee that all risk is eliminated.
What Is a Medical Device Risk Management File?
The risk management file collects the records produced by the process: the risk management plan, hazard and risk analyses, evaluation against acceptability criteria, control measures and their verification, the overall residual risk evaluation, and the risk management report. It provides traceability from each hazard to its control and evidence, and it is a key part of technical documentation.
Is ISO 14971 Compliance Mandatory?
ISO 14971 is a voluntary consensus standard, but the underlying obligation to manage risk is not voluntary. EU MDR Annex I requires a risk management system, and FDA's quality requirements expect risk management, with ISO 14971 widely used and recognized as a way to demonstrate it. Which edition and version is harmonised or recognized depends on the jurisdiction, so check the current Official Journal listing and FDA's recognized consensus standards database.
Medical Device Biological Evaluation Under ISO 10993
Biological evaluation addresses risks from patient-contacting materials. It considers intended clinical use, contact type and duration, available evidence, and biological hazards, and it is conducted as part of the overall risk management process rather than separately. A detailed discussion is available in our guide to toxicological risk assessment of medical devices under ISO 10993.
Edition status is worth checking. ISO 10993-1:2025, the sixth edition, was published in November 2025 and replaces the 2018 edition, based on industry summaries; regulators recognize editions on their own timelines, so confirm what applies to your submission.
Medical Device Biocompatibility Assessment
Typical endpoints include cytotoxicity (cell damage), sensitization (allergic response), irritation (local response), systemic toxicity, genotoxicity, and implantation effects, with others added by device type, such as hemocompatibility. Which endpoints matter depends on contact type, duration, and materials, and addressing an endpoint does not always require a new physical test. Existing data, chemical characterization, and justified rationales can contribute.
Biological Evaluation Plan (BEP)
The BEP is prepared first. It describes the device, intended use, materials, contact categorization, available evidence, relevant endpoints, data gaps, and the proposed strategy with scientific justification.
Biological Evaluation Report (BER)
The BER documents the outcome: evidence reviewed, test and characterization results, toxicological conclusions, remaining uncertainties, and the conclusion on biological safety. It feeds the risk management file.
How ISO 10993 and ISO 14971 Work Together
ISO 14971 defines the overall risk process. ISO 10993-1 applies that process to biological hazards. The biological evaluation supplies hazard and risk conclusions that are integrated into the risk management file. ISO 10993 does not replace ISO 14971; it operates within it.
Medical Device Toxicological Risk Assessment
Toxicological risk assessment evaluates whether patient exposure to chemicals released from a device is acceptable. It considers chemical hazards, material composition, estimated patient exposure, toxicological data, dose-response relationships, acceptable exposure levels, margin of safety, risk characterization, and uncertainty. It is a specialized discipline closely related to broader toxicological risk assessment used across regulated industries.
Why Is Toxicological Evaluation Important?
A device material can be widely used and still release a substance at a dose that matters for a particular patient group, contact site, or duration. Toxicological evaluation turns a list of detected chemicals into a risk judgment, supporting evidence-based decisions about whether additional testing or design changes are needed.
ISO 10993-17 and Toxicological Risk Assessment
ISO 10993-17 describes establishing allowable limits for leachable substances and the associated risk assessment approach. Verify the applicable published edition before citing it. Conclusions depend on exposure assumptions, chemical data quality, and the device's intended use, and these assumptions should be stated transparently.
Chemical Characterization for Medical Device Safety Assessment
Chemical characterization identifies what a device is made of and what it can release. That includes material composition and constituents, extractables and leachables, processing residues, sterilization residues such as ethylene oxide, degradation products, and the resulting chemical exposure to the patient.
ISO 10993-18 Chemical Characterization
ISO 10993-18 describes approaches for identifying and quantifying device constituents and extractables. Results are only useful when interpreted: unidentified or unassessed compounds leave a gap in the biological safety argument, which toxicological assessment then addresses.
Chemical Characterization vs Biocompatibility Testing
Chemical characterization tells you what patients could be exposed to; biocompatibility testing observes biological responses. They answer different questions and neither universally replaces the other. In some cases chemistry plus toxicology can support an endpoint without new biological testing, while in others biological testing remains necessary.
Medical Device Safety Testing Requirements
Testing is selected based on the device's classification, intended use, patient contact, design, materials, risk profile, and regulatory pathway. No device requires every test described below.
Biological Safety Testing
Cytotoxicity, sensitization, irritation, and relevant systemic or implantation endpoints are chosen following the biological evaluation, and only where evidence and justification cannot otherwise address them.
Mechanical and Performance Testing
These tests verify structural integrity, fatigue, durability, and functional performance. A fracture or malfunction can be a patient safety hazard, so performance testing often serves as verification of a risk control.
Electrical Safety Testing
Active devices connected to mains or batteries are typically assessed against the IEC 60601 series, including relevant collateral and particular standards, where applicable. Electrical safety also covers electromagnetic compatibility.
Software Safety Evaluation
Devices containing software follow lifecycle processes such as IEC 62304, with software hazards analyzed within the ISO 14971 framework. Cybersecurity may also be relevant, depending on the device and market.
Usability and Human Factors Evaluation
IEC 62366-1 describes usability engineering to reduce use-related risk. Use errors can cause harm even when the device performs as designed, so use-related hazards belong in the risk analysis.
Sterilization and Microbiological Safety
Sterile devices need sterilization validation, sterility assurance, packaging integrity, and where relevant bioburden or endotoxin controls. Reusable devices may need cleaning and reprocessing validation. These topics apply only to devices that are supplied sterile or reprocessed.
Step-by-Step Medical Device Safety Assessment Process
The workflow below is general. Adapt it to the device, classification, and regulatory pathway.
Define device characteristics and intended use. Objective: establish scope. Document description, intended users, patient population, use environment, and reasonably foreseeable misuse.
Identify applicable regulations and standards. Objective: set the requirements. Record the target markets, classification, and relevant standards, noting which edition applies.
Identify potential hazards. Objective: build the hazard list. Review biological, chemical, mechanical, electrical, software, and usability hazards as applicable.
Estimate and evaluate risks. Objective: judge acceptability. Apply severity, probability, and the criteria defined in the risk management plan.
Develop and implement risk controls. Objective: reduce risk. Prefer inherently safe design, then protective measures, then information for safety.
Plan and conduct relevant safety evaluations. Objective: generate evidence. Use existing data, testing, verification, and validation where justified.
Assess biological and toxicological safety. Objective: address material-related hazards. Apply ISO 10993-1 evaluation, chemical characterization, and toxicological assessment where needed.
Verify risk controls and evaluate residual risks. Objective: confirm effectiveness. Record verification evidence and evaluate residual and overall risk.
Prepare safety assessment documentation. Objective: make the argument reviewable. Document methods, evidence, conclusions, and traceability.
Review post-market information and update the assessment. Objective: keep the file current. New complaints, vigilance data, literature, or design and process changes can trigger reassessment.
Medical Device Safety Assessment Requirements Under EU MDR
EU MDR 2017/745 sets safety and performance requirements for devices placed on the EU market. Manufacturers demonstrate conformity through risk management, biological safety evidence, clinical evaluation, performance evidence, technical documentation, and post-market surveillance, with the conformity assessment route depending on device class.
EU MDR General Safety and Performance Requirements
Annex I contains the General Safety and Performance Requirements (GSPRs). They include a risk management system, requirements on chemical, physical, and biological properties, and requirements for devices that incorporate substances. Manufacturers show conformity with each applicable GSPR and justify any that do not apply.
EU MDR Technical Documentation
Annex II describes the technical documentation, including device description, design and manufacturing information, the GSPR checklist, benefit-risk analysis and risk management, and verification and validation evidence. Annex III covers technical documentation on post-market surveillance.
Biological Safety Assessment Under EU MDR
Biological evaluation, chemical characterization, and toxicological evidence are used to demonstrate conformity with the chemical and biological requirements in Annex I. The depth depends on the device's contact and risk, and notified bodies review the rationale as part of the technical documentation.
Does EU MDR Require ISO 14971 and ISO 10993?
EU MDR itself requires risk management and biological safety, not specific standards. Harmonised standards offer a way to presume conformity with the requirements they cover, but only for the versions cited in the Official Journal. Applying a standard does not automatically establish conformity with every MDR requirement.
Medical Device Safety Assessment for FDA Regulatory Submissions
FDA regulates devices under a risk-based framework. Devices are classified, and the class determines applicable regulatory controls and the premarket pathway. Safety and performance evidence, risk management documentation, recognized consensus standards, and biocompatibility evaluation support the submission. FDA has also been implementing its Quality Management System Regulation, which aligns with ISO 13485; check the current status on FDA's website.
FDA 510(k) Submissions
A 510(k) demonstrates substantial equivalence to a legally marketed predicate device. Safety and performance evidence, including biocompatibility and testing where relevant, supports the comparison. A successful 510(k) results in clearance, not approval.
FDA De Novo Requests
The De Novo pathway applies to eligible novel devices of low to moderate risk with no suitable predicate. FDA evaluates whether general and special controls provide reasonable assurance of safety and effectiveness, and a granted request is an authorization that creates a new classification.
FDA Premarket Approval (PMA)
PMA applies to the highest-risk devices and generally requires scientific evidence, often including clinical data, that demonstrates a reasonable assurance of safety and effectiveness. A successful PMA results in approval.
FDA Biocompatibility Evaluation
FDA has issued guidance on using ISO 10993-1 for biological evaluation in premarket submissions, and ISO 10993 parts appear in its recognized consensus standards database. Guidance represents FDA's current thinking and is not a legal requirement, so confirm the edition and expectations that apply to your submission.
EU MDR vs FDA Medical Device Safety Assessment Requirements
No. A safety assessment contributes evidence, but the outcome depends on the applicable pathway and the full body of required evidence, including performance, quality systems, labeling, and sometimes clinical data. Clearance, approval, authorization, and classification decisions are different outcomes under different pathways.
EU MDR vs FDA Medical Device Safety Assessment Requirements
The two systems share scientific foundations but are not equivalent. EU MDR conformity assessment and FDA premarket review follow different legal frameworks, so evidence prepared for one should be checked against the other.
Medical Device Safety Assessment Documentation Checklist
Documentation requirements vary by device type, classification, and regulatory pathway. Items that may be relevant include:
Device description and intended use
Applicable regulatory requirements
Risk management plan
Hazard identification, risk analysis, and risk evaluation
Risk control documentation
Verification and validation evidence
Biological Evaluation Plan and Report, where applicable
Chemical characterization evidence
Toxicological risk assessment, where applicable
Relevant test reports
Clinical or performance evidence
Benefit-risk justification
Residual risk evaluation and risk management review
Technical documentation
Post-market surveillance planning
Medical Device Safety Assessment for Implantable Medical Devices
Implantable devices usually need a more extensive, device-specific evaluation because contact with tissue is prolonged and failures are hard to correct. Considerations include implantation-related biological effects, material degradation, long-term exposure and chemical release, toxicological risk, mechanical integrity and fatigue, device performance over time, and long-term safety evidence.
Clinical considerations and post-market monitoring matter more as well, since some risks only appear after years of use. Testing and evidence depend on the implant's design, materials, and intended use, so no universal test list applies.
Common Medical Device Safety Assessment Mistakes
Incomplete hazard identification is the most damaging error because every later step builds on it. Teams focus on obvious mechanical hazards and miss chemical, software, or use-related hazards. A structured hazard list across all categories, reviewed by a multidisciplinary team, reduces this risk.
Weak risk management planning, such as undefined acceptability criteria, leads to inconsistent decisions. Incorrect application of standards, for example treating a standard as a checklist or citing an outdated edition, creates avoidable review questions. Missing biological safety evidence, inadequate toxicological assessment, and insufficient chemical characterization leave gaps that surface late; plan them early and document justifications.
Poor verification of risk controls, incomplete technical documentation, and confusing FDA and EU MDR requirements are also common. The last frequent failure is not reassessing risk after design, material, supplier, or manufacturing changes. Building change control triggers into the quality system prevents the file from going stale.
Medical Device Safety Assessment Checklist for Manufacturers
Define intended use and device characteristics
Identify applicable regulatory pathways
Determine relevant standards and editions
Prepare a risk management plan
Identify potential hazards
Evaluate risks and risk acceptability
Implement risk control measures
Verify risk control effectiveness
Evaluate biological safety where applicable
Review chemical characterization needs
Conduct toxicological risk assessment where justified
Complete applicable safety testing
Evaluate residual risks
Document benefit-risk conclusions where relevant
Prepare required technical documentation
Review FDA or EU MDR requirements
Establish post-market monitoring and reassessment processes
When Should Manufacturers Hire a Medical Device Safety Assessment Consultant?
Specialist support is useful when judgment or specialized toxicology drives the outcome. Typical triggers include new device development, FDA submissions and EU MDR technical documentation, complex biological evaluations, implantable devices, toxicological data gaps, chemical characterization challenges, and risk management documentation gaps. Material or manufacturing changes, regulatory deficiency responses, and limited in-house toxicology expertise are also common reasons. A structured toxicology data gap analysis can show which evidence is already adequate and which is missing, helping avoid unnecessary testing. Consultants can strengthen the evidence and documentation, but they cannot promise regulatory outcomes.
How SciQra Supports Medical Device Safety Assessment
SciQra provides toxicology and regulatory support for medical device manufacturers, including medical device toxicological risk assessment, biological safety evaluation, and biocompatibility assessment support. Related work includes interpreting chemical characterization data, developing Biological Evaluation Plans, preparing Biological Evaluation Reports, and identifying regulatory evidence gaps.
Support also covers scientific literature evaluation and safety documentation, within SciQra's wider regulatory compliance and toxicology consulting services. SciQra acts as a scientific and regulatory support partner and does not guarantee regulatory outcomes. Need support with medical device safety assessment, biological evaluation, or toxicological risk assessment? Contact SciQra to discuss your device-specific safety and regulatory documentation requirements.
Key Takeaways
Medical device safety assessment is a lifecycle, risk-based process, not a single test.
Patient and user safety drive hazard identification, risk evaluation, and control selection.
ISO 14971 provides the risk management framework but does not guarantee compliance on its own.
ISO 10993 applies biological evaluation within risk management and does not replace ISO 14971.
Toxicological risk assessment interprets chemical exposure to judge patient risk.
Chemical characterization shows what a device can release and does not universally replace biological testing.
Safety testing is selected by device risk, contact, materials, and pathway; no device needs every test.
EU MDR requires risk management and conformity with Annex I through technical documentation and conformity assessment.
FDA pathways differ: 510(k) clearance, De Novo authorization, and PMA approval are different outcomes.
Technical documentation and post-market monitoring keep the safety argument current across the lifecycle.
Conclusion
Medical device safety assessment brings together risk management, biological evaluation, toxicology, testing, and documentation into one defensible argument that a device is acceptably safe for its intended use. ISO 14971 supplies the process, ISO 10993 addresses biological hazards, and chemical characterization and toxicological risk assessment interpret material-related exposure.
EU MDR and FDA expectations differ, so evidence should be planned with the target pathway in mind and kept current through post-market information. A well-run medical device safety assessment strengthens a submission but does not guarantee its outcome. If you want expert input on your device's safety evidence, SciQra's team is available to discuss your requirements.
Frequently Asked Questions
What is medical device safety assessment and why is it important?
It is a structured evaluation that identifies hazards, evaluates risks, applies controls, and documents acceptable residual risk for a device's intended use. It matters because it protects patients, guides design decisions, and gives regulators traceable evidence. It extends across the lifecycle and is broader than any single laboratory test.
How do manufacturers conduct a medical device risk assessment?
They define the device and intended use, identify hazards and hazardous situations, estimate severity and probability, and compare risks with predefined acceptability criteria. Controls are then applied and verified, residual risk is evaluated, and results are documented in the risk management file and updated with post-market information.
What is the role of ISO 14971 in medical device safety assessment?
ISO 14971 is the international standard for medical device risk management. It provides the process for planning, analyzing, evaluating, controlling, and reviewing risk across the lifecycle. It does not set safety limits or eliminate all risk, and it does not independently guarantee regulatory compliance.
How does ISO 10993 support medical device biological safety?
The ISO 10993 series provides a framework for evaluating biological risks from patient-contacting materials. ISO 10993-1 guides evaluation based on contact type, duration, and materials, while other parts address methods such as chemical characterization and toxicological risk assessment. It operates within ISO 14971 risk management.
Is biocompatibility testing required for every medical device?
No. Biological evaluation is required for relevant risks, but laboratory testing is not required for every endpoint. Existing evidence, material characterization, and scientifically justified rationales can address some endpoints. Testing is added where evidence is insufficient, and regulators may have expectations for particular device types.
What are the medical device safety assessment requirements under EU MDR?
EU MDR requires conformity with the General Safety and Performance Requirements in Annex I, including risk management and chemical and biological safety. Manufacturers prepare technical documentation under Annexes II and III, conduct clinical evaluation, and maintain post-market surveillance. Conformity assessment routes depend on device class.
What safety assessment evidence does the FDA require for medical devices?
It depends on classification and pathway. A 510(k) generally shows substantial equivalence supported by performance and safety evidence, De Novo evaluates controls for novel low-to-moderate risk devices, and PMA requires evidence of safety and effectiveness. Biocompatibility, risk management, and testing support submissions according to FDA guidance.
What is the role of chemical characterization and toxicological risk assessment?
Chemical characterization identifies constituents and extractables or leachables that could reach the patient. Toxicological risk assessment evaluates whether the resulting exposure is acceptable using hazard data, exposure estimates, and acceptable limits. Together they can support biological safety conclusions, though sufficiency depends on the device and data.
What documentation is needed for medical device safety assessment?
Typically the risk management file, including plan, hazard and risk analyses, control verification, and residual risk evaluation. Depending on the device, it may include the BEP and BER, chemical characterization and toxicological assessments, test reports, clinical evidence, benefit-risk justification, and technical documentation. Requirements vary by pathway.
Does completing a medical device safety assessment guarantee FDA approval or EU MDR conformity?
No. A safety assessment contributes required evidence but does not independently authorize market access. FDA and notified-body reviews consider the full submission, including performance, clinical, quality, and labeling evidence. Outcomes also differ by pathway: clearance, authorization, approval, or CE marking.